[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
We used a new chemotherapy regimen for the treatment of 28 consecutive patients with relapsed AML. The regimen consisted of low-dose cytosine arabinocide (ara-C), low-dose aclarubicin and concurrent use of G-CSF (CAG regimen). Twenty four out of 28 patients (86%) achieved complete remission (CR). Median CR duration and median survival were 7 months and 17 months, respectively. Myelosuppression and non-hematological toxicities were apparently low. The CAG regimen seems promising for the treatment of relapsed AML with its low toxicity contributing to a high quality of life for the patient.
Saito
K
K
Third Department of Internal Medicine, Dokkyo University School of Medicine.
D015250:Aclarubicin / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin